Sinovac Biotech (NASDAQ: SVA) is one of 45 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Sinovac Biotech to similar businesses based on the strength of its earnings, profitability, valuation, institutional ownership, analyst recommendations, risk and dividends.
Volatility & Risk
Sinovac Biotech has a beta of 0.1, suggesting that its share price is 90% less volatile than the S&P 500. Comparatively, Sinovac Biotech’s competitors have a beta of 1.18, suggesting that their average share price is 18% more volatile than the S&P 500.
Institutional and Insider Ownership
30.7% of Sinovac Biotech shares are held by institutional investors. Comparatively, 44.9% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 14.9% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Sinovac Biotech and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|Sinovac Biotech||$67.41 million||-$1.07 million||-90.61|
|Sinovac Biotech Competitors||$604.20 million||$110.82 million||-7.38|
Sinovac Biotech’s competitors have higher revenue and earnings than Sinovac Biotech. Sinovac Biotech is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
This table compares Sinovac Biotech and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Sinovac Biotech Competitors||-12,886.85%||33.35%||-21.07%|
This is a summary of recent recommendations and price targets for Sinovac Biotech and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Sinovac Biotech Competitors||121||769||1644||59||2.63|
As a group, “Biopharmaceuticals” companies have a potential upside of 21.64%. Given Sinovac Biotech’s competitors higher possible upside, analysts clearly believe Sinovac Biotech has less favorable growth aspects than its competitors.
Sinovac Biotech competitors beat Sinovac Biotech on 7 of the 9 factors compared.
About Sinovac Biotech
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company’s pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
What are top analysts saying about Sinovac Biotech Ltd.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sinovac Biotech Ltd. and related companies.